[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lichen-planopilaris\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lichen-planopilaris":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100630459","phase-2-safety-and-biomarker-responses-of-delgocitinib-jak123tyk2-inhibitor-in-central-centrifugal-cicatricial-alopecia-and-lichen-planopilaris-100630459",false,"NCT07487948","Safety and Biomarker Responses of Delgocitinib (JAK1,2,3\u002FTYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris","A Pilot Study to Assess Safety and Biomarker Responses of Delgocitinib (JAK1,2,3\u002FTYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris","Inclusion Criteria:\n\n* Participants of any gender, age 18 years or older, at the time of informed consent at Screening.\n* Participants who are willing and able to adhere to the study visit schedule and comply with protocol requirements.\n* Participant self-reports a history of at least 6 months of CA (LPP or CCCA). Diagnosis will be made clinically (according to the LPPAI10, and\u002For CHLG11) and\u002For histopathologically.\n* Participants who are females of childbearing potential must have a negative urine pregnancy test at screening and must be practicing an adequate and medically acceptable method of birth control for at least 30 days prior to Day 0 and at least 28 days after the last dose of study drug. Acceptable methods of birth control include intrauterine device (IUD) oral, transdermal, implanted or injected hormonal contraceptives (must have been initiated at least 1 month before entering the study); tubal ligation; abstinence; barrier methods with spermicide. If not of child-bearing potential, Participants must have a sterile or vasectomized partner; have had a hysterectomy, a bilateral oophorectomy or be clinically diagnosed infertile; or be in a menopausal state for at least a year.\n* Participant is judged to be in otherwise good overall health following a detailed medical and medication history, physical examination, and laboratory testing.\n\nExclusion Criteria:\n\n* Participants of hair loss is indeterminable and\u002For they have concomitant causes of alopecia, such pregnancy-related, drug-induced, telogen effluvium, or advanced androgenetic alopecia.\n* Participant has a history of CA for ≥ 4 years since the disease onset, severe fibrosing disease, or very rapid hair loss at screening.\n* Participant has a history of moderate to severe keloids on the scalp, as determined by clinical examination at screening.\n* Other scalp disease that may impact assessment (e.g., scalp psoriasis, dermatitis, etc.).\n* Participant is pregnant or breastfeeding.\n* Participation in other studies involving investigational drug(s) within 4 weeks or within 5 half-lives (if known), whichever is longer, prior to study entry and\u002For during study participation (de novo patients only).\n* Active systemic diseases that may cause hair loss (e.g., systemic lupus erythematosus, thyroiditis, systemic sclerosis, etc.).\n* Any Psychiatric condition in the opinion of the investigator precludes participation in the study.\n* Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (particularly thyroid disease which can be associated with hair loss), pulmonary, cardiovascular, psychiatric, immunologic\u002Frheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator, the participant is inappropriate for entry into this study, or unwilling\u002Funable to comply with STUDY PROCEDURES.\n* History of thromboembolic events including DVT and PE or history of inherited coagulopathies.\n* Any present malignancies or history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.\n* History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.\n* History of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 0.\n* Active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 0 or superficial skin infection within 1 week prior to Baseline.\n* Considered in imminent need for surgery or with elective surgery scheduled to occur during the study.\n* Have an active history of alcohol or substance abuse within 1 year prior to Day 0.\n* Participant has any uncertain or clinically significant laboratory abnormalities that may affect interpretation of study data or endpoints, at determined by the PI.\n* History of adverse systemic or allergic reactions to components of study drug.\n* Use of systemic immunosuppressive medications, including, but not limited to, cyclosporine, systemic corticosteroids, mycophenolate mofetil, azathioprine, methotrexate, within 8 weeks prior to baseline visit.\n* Use of other non-biologic systemic agent for CA, including, 5α-reductase inhibitors, hydroxychloroquine, or retinoids, within 4 weeks prior to baseline visit.\n* Use of an intralesional corticosteroids or oral JAK inhibitor (tofacitinib, ruxolitinib, or any JAK1\u002FTYK2 product) within 4 weeks prior to the baseline visit.\n* Participant has used topical corticosteroids, and\u002For tacrolimus, and\u002For pimecrolimus or cyclosporine within 1 week before the baseline visit.\n* Participant has been previously treated with biological drugs in the last 12 weeks for other indications.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study evaluates the safety, tolerability, and biomarker effects of twice-daily topical delgocitinib 2% cream in adults with lichen planopilaris (LPP) or central centrifugal cicatricial alopecia (CCCA) over a 48-week treatment period. Approximately 30 participants will be enrolled: 15 CCCA and 15 LPP. The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS).",[26,27],"Central Centrifugal Cicatricial Alopecia","Lichen Planopilaris","RECRUITING","2026-06-02",{"date":31,"type":32},"2026-06-04","ACTUAL",{"date":34,"type":32},"2026-05-19",{"date":36,"type":20},"2027-12-31",{"name":38,"class":39},"Icahn School of Medicine at Mount Sinai","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100633893","phase-2-a-phase-23-study-of-brepocitinib-in-adults-with-lichen-planopilaris-100633893","NCT07532603","A Phase 2\u002F3 Study of Brepocitinib in Adults With Lichen Planopilaris","A Phase 2\u002F3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris","ALPINE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Scalp biopsy consistent with LPP\n3. Active and symptomatic LPP at screening and baseline-\n4. Weight \\> 40 kg to \\\u003C 130 kg with BMI ≤ 45 kg\u002Fm2\n\nExclusion Criteria:\n\n1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).\n2. High risk of thrombosis or cardiovascular disease\n3. High risk of herpes zoster\n4. Active or recent infection",{"count":50,"type":20},342,[23,52],"PHASE3","This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris",[27],[56,57],"brepocitinib","lichen planopilaris","2026-04-09",{"date":60,"type":32},"2026-04-16",{"date":62,"type":32},"2026-03-19",{"date":64,"type":20},"2029-07-31",{"name":66,"class":67},"Priovant Therapeutics, Inc.","INDUSTRY",5,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":40},"100555489","the-effectiveness-of-hydroxychloroquine-versus-methotrexate-in-the-treatment-of-lichen-planopilaris-in-routine-clinical-care-a-patient-preference-trial-100555489","NCT06512753","The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial","HEMLET","Inclusion Criteria:\n\n* Age of 18 years and older.\n* Diagnosed with LPP.\n* Willingness to provide informed consent for participation in the study.\n* No contraindications or known allergies to HCQ or MTX.\n\nExclusion Criteria:\n\n* Histopathological different diagnosis than LPP.\n* Inability to adhere to the study protocol, including medication intake, clinic visits, and questionnaire completion.\n* Patients who are ineligible for the HCQ arm (due to contraindications), are automatically included in the MTX arm.\n* Contraindications HCQ:\n\nretinopathy and\u002For maculopathy\n\nmyasthenia gravis\n\nbody weight less than 35 kg\n\nPatients who are ineligible for the MTX arm (due to contraindications), are automatically included in the HCQ arm.\n\n\\- Contraindications MTX:\n\nConception (both male and female) and lactation\n\nSevere kidney or liver dysfunction (fibrosis, cirrhosis) or alcohol abuse\n\nBone marrow hypoplasia, immunodeficiency\n\nAnemia, leukopenia, or thrombocytopenia\n\nPoor nutritional status (low albumin)\n\nHypersensitivity or allergy to MTX\n\nLung toxicity due to MTX or significant reduction in lung function.","80 Years",{"count":78,"type":20},56,"OBSERVATIONAL","Rationale Lichen planopilaris (LPP) is a prevalent form of cicatricial alopecia, predominantly affecting women and causing irreversible hair loss. Hydroxychloroquine (HCQ) and methotrexate (MTX) are the most frequently used systemics for treatment of LPP in daily practice. Due to the absence of well-established treatment guidelines, this study aims to evaluate the effectiveness of HCQ and MTX in routine clinical care.\n\nObjective(s) To investigate the effectiveness of HCQ and MTX in the treatment of adults with lichen planopilaris in routine clinical care.\n\nStudy type Prospective, patient preference clinical trial with a duration up to 48 weeks in accordance with the routine clinical care guidelines.\n\nStudy population This study will include adults (≥18 years) diagnosed with LPP.\n\nMethods Patients will choose between HCQ and MTX treatment as in routine clinical care, receiving follow-up in accordance with standard clinical practices. They will not be randomized. The primary endpoint is the measurement of the Lichen Planopilaris Activity Index (LPPAI) at the 6-months, providing a quantitative assessment of the disease's activity and response to the selected treatment. The Skindex-29 questionnaire will be conducted at each visit, allowing evaluation of the impact on patients' quality of life.",[27,82],"Cicatricial Alopecia",[84,85,86,87],"Lichen planopilaris","Cicatricial alopecia","Hydroxychloroquine","Methotrexate","2024-07-16",{"date":90,"type":32},"2024-07-22",{"date":92,"type":32},"2024-07-01",{"date":94,"type":20},"2026-07-01",{"name":96,"class":39},"Erasmus Medical Center"]